Avid Radiopharmaceuticals

Avid Radiopharmceuticals Clinical Trials

In 2011, Dr. John H. Fullerton, who leads The Clinical Research Division of Hampton Health, Ltd., was chosen to be an investigator in the widely anticipated clincial trials of AVID Radiopharmaceuticals (18F-AV-45-A17 Study) conducted by Health Diagnostics of California, LLC with Dr. Stephen R. Bunker (one of the foremost imaging diagnosticians in the world). Hampton Health, Ltd. ranked 7th place for participant qualification and enrollment in this large multi-center study that involved 18 sites nationally.

On May 24th 2012 Dr. Fullerton was interviewed by KTVU Channel 2 News regarding the Clinical Trials of Avid Radiopharmaceuticals, "some calling it the holy grail of Alzheimer's Research" as reported by Channel 2.

AVID RADIOPHARMCEUTICALS CLINICAL TRIALS

The AVID study (18F-AV-45-A17) focused on respondents age 50 and above who experienced some form of memory loss, (including MCI – Mild Cognitive Impairment), to become part of a compensated study which utilized a specifically designed PET scan (with the addition of the unique radiopharmaceutical compound Amyvid™ or florbetapir F 18) for the augmented detection of Alzheimer's Disease and read by Dr. Stephen R. Bunker.

Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and monitoring of chronic human diseases, was acquired by Eli Lilly and Company in December of 2010.

Print